SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-004767
Filing Date
2019-05-10
Accepted
2019-05-10 06:11:30
Documents
61
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20190331x10q.htm 10-Q 1753446
2 EX-10.2 tbph-20190331ex102ce7b68.htm EX-10.2 68260
3 EX-31.1 tbph-20190331ex311e3d1ec.htm EX-31.1 14936
4 EX-31.2 tbph-20190331ex3127e4c41.htm EX-31.2 15499
5 EX-32 tbph-20190331xex32.htm EX-32 17483
  Complete submission text file 0001558370-19-004767.txt   5447183

Data Files

Seq Description Document Type Size
6 EX-101.INS tbph-20190331.xml EX-101.INS 885191
7 EX-101.SCH tbph-20190331.xsd EX-101.SCH 42014
8 EX-101.CAL tbph-20190331_cal.xml EX-101.CAL 47684
9 EX-101.DEF tbph-20190331_def.xml EX-101.DEF 165915
10 EX-101.LAB tbph-20190331_lab.xml EX-101.LAB 384857
11 EX-101.PRE tbph-20190331_pre.xml EX-101.PRE 296047
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 19812724
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences